Immunocytochemistry on lung cancer patients tumours to assess response to therapy
November 2016
Yale University School of Medicine, New Haven, USA
PD-L1 is a transmembrane protein targeted by monoclonal antibody therapy targets in cancer. Yet, it has highly heterogeneous expression in tumours. In the present study, the researchers examined the expression by immunohistochemistry and quantitative immunofluorescence on tissues obtained from lung cancer patients and compared readings between pathologists. The results should allow for better assessment of the response to therapy.
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
David L Rimm
Added on: 07-28-2021
[1] https://www.nature.com/articles/modpathol2016186[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
